From American Pharmacists Association email, published Sept. 9: Taking up APhA’s recommendation, and in a win for pharmacists and patients, the U.S. Department of Health and Human Services (HHS) has amended the PREP Act to grant licensed pharmacists the authority to order and administer FDA-authorized, approved, licensed, or cleared COVID-19 therapeutics. The amendment also authorizes pharmacy interns and pharmacy technicians to administer these COVID-19 therapeutics.
The amendment gives patients crucial access to post-exposure prophylaxis such as monoclonal antibodies for COVID-19 emergency use, as well as any future oral therapeutics. The PREP Act preempts state requirements, such as more limited licensing or scope of practice requirements, that effectively prohibit a qualified person from prescribing, dispensing, or administering covered COVID-19 therapeutics.
Related: A quick fact sheet about the treatments that are currently subject to the amended PREP Act for COVID-19 and when/how they can be used, compiled by student pharmacists from University of Minnesota College of Pharmacy REGEN-COV information for healthcare providers
Print Page
Email to a Friend